GSA Capital Partners’s OptimizeRx OPRX Stock Holding History

GSA Capital Partners’s Portfolio OPRX Stock Details OPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,604	Closed	-$155K	–	2052
2025 Q4	$155K	Buy	+12,604	New	+$206K	0.01%	1468
2025 Q1	–	Sell	-20,661	Closed	-$100K	–	1960
2024 Q4	$100K	Buy	+20,661	New	+$115K	0.01%	1512
2023 Q4	–	Sell	-64,143	Closed	-$499K	–	1795
2023 Q3	$499K	Buy	64,143 +1,816	+3%	+$19.8K	0.04%	807
2023 Q2	$891K	Buy	62,327 +7,471	+14%	+$106K	0.09%	374
2023 Q1	$803K	Buy	54,856 +24,517	+81%	+$410K	0.08%	438
2022 Q4	$510K	Sell	30,339 -19,985	-40%	-$346K	0.06%	588
2022 Q3	$746K	Buy	+50,324	New	+$995K	0.1%	303
2020 Q4	–	Sell	-15,481	Closed	-$323K	–	1498
2020 Q3	$323K	Buy	+15,481	New	+$266K	0.05%	680

Other funds holding OPRX

WCA

Whetstone Capital Advisors Shawnee Mission, Kansas $288M AUM 44.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSA Capital Partners's OPRX Position: Q1 2026 in Review

GSA Capital Partners sold out of OptimizeRx (OPRX) in Q1 2026, closing a stake of 12,604 shares — an estimated $155K sold.

GSA Capital Partners first reported a position in OPRX in Q3 2020 and held it in 8 quarters. The position peaked at $891K in Q2 2023. 127 funds tracked by Wall St. Rank hold OPRX as of Q1 2026.

GSA Capital Partners reported no remaining OptimizeRx position as of Q1 2026 after selling out during the quarter.
GSA Capital Partners sold 12,604 OptimizeRx shares in Q1 2026, an estimated $155K.
GSA Capital Partners first reported a position in OptimizeRx in Q3 2020 and held it in 8 quarters.
GSA Capital Partners's OptimizeRx position peaked at $891K in Q2 2023.
127 funds tracked by Wall St. Rank held OptimizeRx as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.